Guardion Launches Second Ocular Health Formula ‘GlaucoCetin’
June 04 2019 - 7:00AM
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(Nasdaq: GHSI), an ocular health sciences and technologies company
that develops, formulates and distributes condition-specific
medical foods and testing technologies supported by evidence-based
protocols, today announced the launch of the Company’s second
ocular health formula. The proprietary formula for GlaucoCetin is
based on a parent compound, GlaucoHealth, which was created by Dr.
Robert Ritch of the New York Eye and Ear Infirmary. GlaucoHealth
was shown in an IRB-approved clinical trial to reverse
mitochondrial dysfunction in the optic nerve cells of glaucoma
patients. GlaucoCetin is a highly enhanced version of this parent
compound.
Michael Favish, Guardion’s Chief Executive
Officer, commenting on the launch of GlaucoCetin stated, “We are
excited to add GlaucoCetin to our portfolio. It is the first
formula designed specifically to provide enhanced retinal health
and neuroprotection in eye disease patients, with a focus on the
glaucoma market. The glaucoma market represents a $5.9 billion
market and is growing at an estimated 3% annually. GlaucoCetin will
significantly expand patient treatment options for eye doctors and
Guardion’s market reach.”
Dr. Robert Ritch holds the Shelley and Steven
Einhorn Distinguished Chair in Ophthalmology and is surgeon
Director Emeritus and Chief of Glaucoma Services at the New York
Eye and Ear Infirmary. Dr. Ritch has devoted his career to
broadening our understanding of the underlying etiologies and
mechanisms of glaucoma.
Information and risk factors with respect to
Guardion and its business, including its ability to successfully
develop and commercialize its proprietary products and
technologies, may be obtained in the Company’s filings with the
Securities and Exchange Commission (“SEC”) at www.sec.gov.
About Guardion Health Sciences,
Inc.
Guardion is an ocular health sciences company
that develops, formulates and distributes condition-specific
medical foods supported by evidence-based protocols, with an
initial medical food product, Lumega-Z, that addresses a depleted
macular protective pigment, a known risk factor for age-related
macular degeneration (“AMD”) and a significant component of
functional vision performance. Guardion Health Sciences, Inc. has
also developed a proprietary medical device, the MapcatSF®, which
accurately measures the macular pigment density, therefore
providing the only two-pronged evidence-based protocol for the
treatment of a depleted macular protective pigment.
About
VectorVision®
VectorVision®, operating through a wholly-owned
subsidiary of the Company, specializes in the standardization of
contrast sensitivity, glare sensitivity, low contrast acuity, and
ETDRS acuity vision testing. Its patented standardization system
provides the practitioner or researcher the ability to delineate
very small changes in visual capability, either as compared to the
population or from visit to visit. VectorVision®’s CSV-1000 device
is considered the standard of care for clinical trials.
Forward-Looking Statement
Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. These statements
involve unknown risks and uncertainties that may individually or
materially impact the matters discussed herein for a variety of
reasons that are outside the control of the Company, including, but
not limited to, the Company’s ability to raise sufficient financing
to implement its business plan and its ability to successfully
develop and commercialize its proprietary products and
technologies. Readers are cautioned not to place undue reliance on
these forward-looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s filings with the SEC, which are available at
the SEC’s website (www.sec.gov). The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Company
Contact:
Investor Relations Contact:Michael
Favish
Matthew AbenanteChief Executive Officer
Porter, LeVay & Rose, Inc.
Telephone: (212) 564-4700
Telephone: (858)
605-9055 x 201
E-mail:
mfavish@guardionhealth.com
E-mail: matthew@plrinvest.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Sep 2023 to Sep 2024